OGNOrganon & Co.

$13.81+33% 1Y

$13.81

$5.6952 weeks$13.81

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 without data

What the price assumes~−10% a yearderived · Jun 30, 2026

Priced for a decline (~−10% a year). Little growth is priced in even as revenue fell 0% a year over three years, potential value, or a value trap.

Vs its own P/E rangedearest in 21 quartersderived

Expensive vs its own history: P/E 17.7 vs a 5.1 median over 21 quarters (+245% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldtop 5% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Organon & Co. trades at 17.7× earnings against 26.2× for the median Drug Manufacturers - General name, cheaper than its own group.

17.7

Trailing P/E · Drug Manufacturers - General median 26.2 · cheaper than the typical name in its group

Price / sales: 0.58
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 16%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: −10%
Growth the price implies · The price pays for −10% free cash flow growth a year for a decade; the business has delivered +5.0% a year over the last three.